Polycomb factor PHF19 affects AML initiation, patient prognosis, and survival
Science Advances · 2026
DOI: 10.1126/sciadv.aed6757 ↗At a glance
Journal article in Science Advances, 2026. Written by Gianni Paolo Gamarra Figueroa and 9 co-authors. Institution: Centre for Genomic Regulation (CRG), The Barcelona Institute for Science and Technology, Carrer del Doctor Aiguader 88, Barcelona 08003, Spain. Major MEDLINE topics: Leukemia, Myeloid, Acute, Transcription Factors, DNA-Binding Proteins. 83 references. The full text is freely available in PubMed Central. Funded by: Generalitat de Catalunya, Agència de Gestió d’Ajuts Universitaris i de Recerca, Shenzhen Graduate School, Peking University.
Abstract (original language)
Acute myeloid leukemia (AML) is marked by unchecked expansion of undifferentiated myeloid cells. Although oncogenic fusions such as MLL-AF9 can initiate disease, the early steps of leukemogenesis and the role of cell-intrinsic regulators remain unclear. We previously showed that the Polycomb-associated factor Phf19 is required for hematopoietic stem cell (HSC) maintenance and state control in mice and that its loss (Phf19 KO ) impairs HSC function. To define Phf19’s role in transformation, we expressed MLL-AF9 in Phf19 KO hematopoietic cells and performed integrated multiomic analyses. Phf19 deletion promoted acquisition of stemlike features and reduced responsiveness to differentiation-inducing AML therapies. Molecular and functional consequences of Phf19 loss paralleled those observed in the datasets of patients with AML. From these data, we derived a prognostic signature—PHFScore—which reveals previously unrecognized AML survival-correlating genes that robustly stratify patients across distinct cellular origins and leukemogenic stages, underscoring Phf19’s key role in AML biology and prognosis.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Centre for Genomic Regulation (CRG), The Barcelona Institute for Science and Technology, Carrer del Doctor Aiguader 88, Barcelona 08003, Spain.
- Universitat Ramon Llull, Blanquerna School of Health Science, Barcelona 08025, Spain.
- Centre Nacional d'Anàlisi Genòmica (CNAG), Baldiri I Reixac 4, Barcelona 08028, Spain.
- Department of Experimental Oncology, IEO European Institute of Oncology IRCSS, Milan 20139, Italy.
- Department of Oncology and Hematology-Oncology, University of Milan, Milan 20122, Italy.
- Universitat Pompeu Fabra (UPF), Barcelona, Spain.
ORCID profiles: Arantxa Gutierrez, Enrique Blanco, Pedro Vizán, Cecilia Ballaré, Aleksandra Sparavier, Marta Tosto, Saverio Minucci, Lars Velten, Luciano Di Croce
Funding
- Generalitat de Catalunya
- Agència de Gestió d’Ajuts Universitaris i de Recerca
- Shenzhen Graduate School, Peking University
- Spanish Ministry of Science and Innovation
- LaCaixa Foundation
- Ministerio de Ciencia e Innovación
Cite
APA
Gamarra Figueroa, G. P., Gutierrez, A., Blanco, E., Vizán, P., Ballaré, C., Sparavier, A., Tosto, M., Minucci, S., Velten, L., & Di Croce, L. (2026). Polycomb factor PHF19 affects AML initiation, patient prognosis, and survival. Science Advances. https://doi.org/10.1126/sciadv.aed6757
Vancouver
Gamarra Figueroa GP, Gutierrez A, Blanco E, Vizán P, Ballaré C, Sparavier A, et al. Polycomb factor PHF19 affects AML initiation, patient prognosis, and survival. Science Advances. 2026. doi:10.1126/sciadv.aed6757
BibTeX
@article{GamarraFigueroa2026,
author = {Gamarra Figueroa, Gianni Paolo and Gutierrez, Arantxa and Blanco, Enrique and Vizán, Pedro and Ballaré, Cecilia and Sparavier, Aleksandra and Tosto, Marta and Minucci, Saverio and Velten, Lars and Di Croce, Luciano},
title = {Polycomb factor PHF19 affects AML initiation, patient prognosis, and survival},
journal = {Science Advances},
year = {2026},
doi = {10.1126/sciadv.aed6757}
}
EUVIMED